Tech Company Inital Public Offerings

4D Molecular Therapeutics IPO

Based in Emeryville, 4D Molecular Therapeutics is now a public company.

Transaction Overview

Announced On
12/10/2020
Transaction Type
IPO
Amount
$193,200,000
Proceeds Purpose
Management says it will use the net proceeds from the IPO as follows:$65.0 million to $70.0 million to fund our ongoing and planned clinical and preclinical development of our product candidates, including ongoing clinical trials for 4D-310 and 4D-125 and IND-enabling study activities for 4D-150 and 4D-710;$30.0 million to $35.0 million to fund the further development and expansion of our pipeline including to complete lead optimization and IND-enabling studies for 4D-135, and potentially other research candidates;$5.0 million to $10.0 million to fund the continued expansion of our manufacturing capabilities and facilities; andany remaining amounts for working capital and other general corporate purposes.

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
5858 Horton St. 455
Emeryville, CA 94608
USA
Email Address
Overview
4D Molecular Therapeutics (Nasdaq: FDMT) designs, develops and commercializes transformative gene therapeutic products for serious unmet medical conditions.
Profile
4D Molecular Therapeutics LinkedIn Company Profile
Social Media
4D Molecular Therapeutics Company Twitter Account
Company News
4D Molecular Therapeutics News
Facebook
4D Molecular Therapeutics on Facebook
YouTube
4D Molecular Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
David Kirn
  David Kirn LinkedIn Profile  David Kirn Twitter Account  David Kirn News  David Kirn on Facebook
Chief Financial Officer
August Moretti
  August Moretti LinkedIn Profile  August Moretti Twitter Account  August Moretti News  August Moretti on Facebook
Chief Operating Officer
Theresa Janke
  Theresa Janke LinkedIn Profile  Theresa Janke Twitter Account  Theresa Janke News  Theresa Janke on Facebook
Chief Scientific Officer
Peter Francis
  Peter Francis LinkedIn Profile  Peter Francis Twitter Account  Peter Francis News  Peter Francis on Facebook
Chief Technical Officer
Fred Kamal
  Fred Kamal LinkedIn Profile  Fred Kamal Twitter Account  Fred Kamal News  Fred Kamal on Facebook
VP - Human Resources
Jessica Wilan
  Jessica Wilan LinkedIn Profile  Jessica Wilan Twitter Account  Jessica Wilan News  Jessica Wilan on Facebook


 

 

Browse more venture capital transactions:

Prev: 12/10/2020: HealNow venture capital transaction
Next: 12/10/2020: myInterview venture capital transaction

 

Share this article

 


Where The Data Comes From

Our team works diligently to report on funding rounds that are announced publicly. All VC database entries reported here are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary